About this episode

This episode explores a study on the effects of semaglutide in obese patients with heart failure and type 2 diabetes.

Exploring Semaglutide: Dual Action Therapy for Obesity and Heart Failure In this episode of Hormone Insights, we delve into a 2024 study from the New England Journal of Medicine that examines the effects of semaglutide in obese patients with heart failure, preserved ejection fraction, and type 2 diabetes. For full paper, click here Visit HormoneInsight

More episodes of Hormone Insight

• HORMONE INSIGHT -- THE WEEK IN DIABETES & ENDOCRINOLOGY -- Episode 004 | April 24, 2026 · April 24, 2026 · 14 min
• The Week in Diabetes and Endocrinology April 17, 2026 · April 22, 2026 · 18 min
• Episode 002: LDL Under 55 Wins Big, Medicare Covers GLP-1, and Second Weekly Insulin Emerges -- The Week in Diabetes & Endocrinology (April 10, 2026) · April 9, 2026 · 17 min
• The Week in Diabetes and Endocrinology -- April 3, 2026 · April 5, 2026 · 24 min
• Early Onset Type 2 Diabetes and Tirzepatide (SURPASS Post Hoc Analysis) · June 14, 2025 · 1 min
• Semaglutide vs Canagliflozin for Type 2 Diabetes · December 19, 2024 · 1 min

Explore listener stats, chart rankings, contacts and more on the Hormone Insight podcast page.